This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Arena Pharma: Sell-Side Squawks

Stocks in this article: ARNA VVUS

Updated with a Bank of America Merrill Lynch research note published this morning.

SAN DIEGO ( TheStreet) -- Everyone, it seems, has strong opinions about Arena Pharmaceuticals (ARNA) and its obesity drug lorcaserin. As investors wait for FDA to make an approval decision on Wednesday, here's a summary of what Wall Street's sell-side analysts have been saying recently about Arena and lorcaserin (with ancillary comments about obesity drug competitor Vivus (VVUS).)

Bank of America Merrill Lynch
Last Arena note: June 26
Rating/price target: Underperform/$5
Analyst comments:
"Is prolactin-mediated cancer really a non-human risk? Several posters and oral presentations at the Endocrinology conference in recent days were focused on the relationship between prolactin levels and various cancers. Recall that Arena hypothesized that the fibroadenoma mammary tumors in lorcaserin-treated rats were due to elevated prolactin levels, which has previously been considered a rat-specific mechanism and not a human risk. The data presented at ENDO and summarized below could reinforce the view among some scientists that there is a causal link between prolactin and human cancers. We believe it is more than likely that the FDA will issue a Complete Response Letter for locaserin by the 6/27 decision date in order to develop risk mitigation plans or to collect more data such as from additional carcinogenicity studies."
From a May 11 note: "Our risk adjusted sales estimate for lorcaserin in 2017 is $530mn, which is below our $900mn and $1.8bn respective risk-adjusted sales estimates for Orexigen's Contrave and Vivus' Qnexa, driven largely by relatively efficacy differences."
Arena's first profitable year: Net income of $6 million in 2014.

BMO Capital Markets
Last Arena note: June 25
Rating/price target: Market perform/$10
Analyst comments:
"We are reducing our rating on ARNA to MARKET PERFORM from OUTPERFORM , but maintaining our $10 price target. With ARNA shares trading at our target price we believe the stock is fully valued and pricing in timely approval, absence of REMS and low burden of monitoring. Upside potential to our $1.6B global peak sales estimate in 2020 and to our 2017 US sales estimate of $550M is difficult to ascertain, in advance of approval, labeling review and early-market trends, but we would highlight incremental $0.14 EPS for every $100M in incremental sales in our 2017 valuation year. Downside risk to nonapproval is low, in our opinion; however, with 17 of 23 panel members recommending regular monitoring for valvulopathy and with 9 of 23 specifically recommending a REMS or regular ECHO monitoring, downside risk to estimates could emerge." KEY POINTS
"In reviewing the transcript from the May 10, 2012, EMDAC panel meeting it is clear that the majority of panel members viewed the benefit-risk profile of lorcaserin as favorable but that a majority was also concerned regarding heart valve risk. To the extent that timing of lorcaserin approval, final labeling and ultimate commercial potential could be affected by FDA's view toward heart valve risk, we believe that it is instructive to review key panel comments around the rationale for the positive vote and monitoring recommendations. We would note that in total 17 of 23 EMDAC panel members recommended some form of heart valve monitoring with 9 of 23 panel members recommending a REMS or routine ECHO monitoring."
Arena's first profitable year: Net income of $27 million in 2015.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs